Evidence map›Paper›PMID 23886894›Full record

ReviewSeminars in immunology2013

Systems immunogenetics of vaccines.

Michael Mooney, Shannon McWeeney, Rafick-Pierre Sékaly

Abstract readReview
In one paragraph

Review in Seminars in immunology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 16 citations in OpenAlex.

  1. Review
  2. Article
  3. Propelling the Pediatric HIV Therapeutic Agenda With Science, Innovation, and Collaboration.Journal of acquired immune deficiency syndromes (1999) · 2018
    Article
  4. Review
  5. Article
  6. Vaccinology in the era of high-throughput biology.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2015
    Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Systems-level analysis of innate immunity.Annual review of immunology · 2014
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 1 country.

Michael MooneyDivision of Bioinformatics & Computational Biology, Department of Medical Informatics & Clinical Epidemiology, Oregon Health & Science University, Oregon, United States.
Shannon McWeeney
Rafick-Pierre Sékaly
Oregon Clinic · USOregon Health & Science University · USVaccine & Gene Therapy Institute of Florida · US

Funding

OREGON CLINICAL AND TRANSLATIONAL SCIENCE INSTITUTEUL1RR024140 · NCRR · OREGON HEALTH & SCIENCE UNIVERSITY · PI ORWOLL, ERIC S. · 2006 to 2011
$61.1M
Understanding the origins of rapid recurrence of pancreatic cancer after resectionP30CA069533 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI Luiz Eduardo Bertassoni · 1997 to 2026
$60.5M
The Burden of Chikungunya and Dengue Infection in KenyaU54AI081680 · NIAID · OREGON HEALTH & SCIENCE UNIVERSITY · PI RYMAN, KATHERINE D · 2009 to 2013
$40.4M
Unlocking Zika Virus Immune Control and Pathogenesis with the Collaborative CrossU19AI100625 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI HEISE, MARK T · 2012 to 2021
$36.6M
Viral reservoirs and sanctuaries in HAART - treated patients: role and mechanismsU19AI096109 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI SCHACKER, TIMOTHY W · 2011 to 2015
$29.5M
TRAINING PROGRAM IN HEALTH INFORMATICST15LM007088 · NLM · OREGON HEALTH & SCIENCE UNIVERSITY · PI WILLIAM R HERSH, Vishnu Mohan · 1992 to 2026
$23.4M
Novel Concepts for the Eradication of HIVDP1DA028871 · NIDA · VGTI FLORIDA · PI SEKALY, RAFICK PIERRE · 2009 to 2013
$4.5M
NCI NIH HHS 5P30CA069533NCI NIH HHS P30 CA069533NCRR NIH HHS 5UL1RR024140NCRR NIH HHS UL1 RR024140NIAID NIH HHS 1U19AI100625NIAID NIH HHS 5U54AI081680NIAID NIH HHS U19 AI096109NIAID NIH HHS U19 AI100625NIAID NIH HHS U54 AI081680NIDA NIH HHS DP1 DA028871NLM NIH HHS 2T15LM007088NLM NIH HHS T15 LM007088
6 · The paper itself

Abstract

Vaccines are the most cost effective public health measure for preventing viral infection and limiting epidemic spread within susceptible populations. However, the efficacy of current protective vaccines is highly variable, particularly in aging populations. In addition, there have been a number of challenges in the development of new vaccines due to a lack of detailed understanding of the immune correlates of protection. To identify the mechanisms underlying the variability of the immune response to vaccines, system-level tools need to be developed that will further our understanding of virus-host interactions and correlates of vaccine efficacy. This will provide critical information for rational vaccine design and allow the development of an analog to the "precision medicine" framework (already acknowledged as a powerful approach in medicine and therapeutics) to be applied to vaccinology.

Indexed as

Drug DiscoverySystems BiologyVaccinesAnimalsHost-Pathogen InteractionsHumansImmunity, ActiveImmunogeneticsMolecular Targeted TherapyVaccinesInfectious diseaseSystems biologyVaccine

Identifiers

PMID23886894
PMCPMC3815469
OpenAlexW2090506114

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.